Results 111 to 120 of about 14,385 (213)

Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens.
Sara Mele, Antonio Pinto, Domenico Galati, Fabrizia Florio, Rosaria De Filippi, Serena Zanotta   +5 more
core   +1 more source

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm. [PDF]

J Hematol Oncol
Budde LE, Del Real MM, Song J, Stiller T, Wang Y, Aribi A, Sandhu K, Nakamura R, Marcucci EC, Wu JJ, Ng K, Clark MC, Wood B, Wagner JR, Paul J, Brown CE, Stein A, Marcucci G, Blanchard MS, Palmer J, Forman SJ.   +20 more
europepmc   +1 more source

Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature. [PDF]

Front Immunol
Yang F, Li D, Lei Y, Liu R, Fu Z, Ma L, Deng B, Ke X, Hu K.   +8 more
europepmc   +1 more source

Antigen-directed p53 restoration in <i>TP53</i>-mutated myeloid neoplasms: a hypothesis and theory perspective. [PDF]

Front Oncol
Medawar G, Pyle S, Baratam P, Coltoff A.
europepmc   +1 more source

Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax. [PDF]

Ann Hematol
Zhang M, Chai X, Zhang X, Lu W, Lyu H, Pu Y, Meng J, Lyu C, Zhao M.   +8 more
europepmc   +1 more source

Cellular immunotherapy for acute myeloid leukemia: from bench to bedside. [PDF]

Immunother Adv
Wang Y, Wu J, Huang X, Xiao Y.
europepmc   +1 more source

Case Report: Blastic plasmacytoid dendritic cell neoplasm mimicking systemic lymphoma: a multidisciplinary diagnostic challenge. [PDF]

Front Med (Lausanne)
Lv B, Rong Q, Li Y, Zhang D.
europepmc   +1 more source

Suggestive characteristic change of CD123⁺dendritic cells in Kikuchi-Fujimoto Disease. [PDF]

J Clin Exp Hematop
Asano S, Mori K, Yamazaki K, Sato H, Naito H, Yamada R, Komohara Y.   +6 more
europepmc   +1 more source

Anti-CD123 Monoclonal Antibody CSL360 [PDF]

, 2020
openaire   +1 more source

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study. [PDF]

J Hematol Oncol
Short NJ, Bataller A, DiNardo CD, Montalban-Bravo G, Wang SA, Wang W, Maiti A, Nguyen D, Hachem MC, Bi TM, Issa GC, Chien KS, Ohanian M, Kadia TM, Loghavi S, Karrar O, Bachireddy P, Hwang H, Huang X, Garcia-Manero G, Ravandi F.   +20 more
europepmc   +1 more source